METAIRIE, La. (WVUE) - A federal judge’s decision last week to restrict compounding pharmacies from producing tirzepatide, the generic version of Eli Lilly’s weight loss drug Zepbound ...

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...

Tirzepatide was previously shown to provide sustained weight reductions in adults with obesity. New longer-term findings in adults with both obesity and prediabetes are summarized in a short video.

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Two recent tools in the battle for weight loss have been showing incredible results: Semaglutide and Tirzepatide. Stephanie Davison from Skin Envy Non-Surgical Weight Loss Center, and Registered ...